Closed · HT942526PRMRPTTDA · CFDA 12.420 · Discretionary
DoW Peer Reviewed Medical, Technology/Therapeutic Development Award
Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- August 6, 2026
- Close date
- 12
- Expected awards
The verdict
DoW Peer Reviewed Medical, Technology/Therapeutic Development Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 12 expected awards. Future funding cycles may be published under the same CFDA number.
- Varies
- award range
- Closed
- application status
- 12
- expected awards
- 12.420
- CFDA program
Opportunity snapshot. This Grants.gov announcement - DoW Peer Reviewed Medical, Technology/Therapeutic Development Award - is cataloged under number HT942526PRMRPTTDA and tied to CFDA assistance listing 12.420, posted by Defense Health Agency Contracting Activity - DHACA. Grants.gov currently shows the opportunity as closed, first posted on May 8, 2026 and last updated on May 14, 2026. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Varies by applicant. The agency has projected $67.2 million in total estimated funding for this announcement. It expects to issue 12 awards. If the agency funds the expected 12 awards from the $67.2 million estimated pool, the average award works out to roughly $5.6 million. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on August 6, 2026. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Varies by applicant
Close Date
August 6, 2026
Posted
May 8, 2026
Est. Total Funding
$67,200,000
Expected Awards
12
Instrument
Grant
Description
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award, a product-driven award mechanism, intends to support the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the congressionally directed FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals. Products can be tangible items, such as drugs or devices, or can be knowledge products, such as clinical decision-making tools or practice guidelines. Products in development should address or have dual purpose potential for the health care needs of military Service Members, Veterans and their Families.Distinctive Features: For the PRMRP Technology/Therapeutic Development Award, the program expects the research proposed will take an already established proof-of-concept or prototype through the final stages of preclinical development. The PRMRP also expects that the research outcome will be a regulatory filing or translation of findings into clinical practice, as applicable.Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $67.2M to fund approximately 12 Technology/Therapeutic Development Award applications with total cost caps of $5.6M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.
Eligibility
Grants.gov lists this opportunity under eligibility category code 99. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
DoW Neurofibromatosis Investigator-Initiated Research Award
DoW Neurofibromatosis Research Academy – Scholar Award
DoW Neurofibromatosis Exploration-Hypothesis Development Award
DOW Combat Readiness – Medical Research Program Translational Research Award
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |